CABA Cabaletta Bio

Cabaletta Bio to Participate in Upcoming Investor Conferences in December

Cabaletta Bio to Participate in Upcoming Investor Conferences in December

PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following investor conferences in December:

  • 7th Annual Evercore HealthCONx Conference: Fireside chat on Wednesday, December 4, 2024, at 7:55 a.m. ET in Coral Gables, FL. Members of management will also be available for one-on-one meetings.



  • Citi’s 2024 Global Healthcare Conference: Members of management will be available for one-on-one meetings on Wednesday, December 4, 2024, in Miami, FL.

A live webcast of the fireside chat will be available on the News and Events section of the Company’s website at . Replays will be available on the website for 30 days.

About Cabaletta Bio

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. CABA-201 is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit  and connect with us on LinkedIn.

Contacts:

Anup Marda

Chief Financial Officer

William Gramig

Precision AQ



EN
26/11/2024

Underlying

CABACabaletta Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cabaletta Bio

 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio to Participate in Upcoming Investor Conferences in Decem...

Cabaletta Bio to Participate in Upcoming Investor Conferences in December PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following investor conferences in December: 7th Annual Evercore HealthCONx Conference: Fireside chat on Wednesday, December 4, 2024, at 7:55 a.m. ET in Coral Gables, FL. Members of management will als...

4h / 36m 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on C...

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 – CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – Compelling clinical responses observed in lupus and myositis patients with up to six months of follow-up; first SSc patient demonstrated an emerging, drug-free clinical response – – All eight patients with active, refractory autoimmune disease discontinued all immunosuppressants prior to CABA-201 in...

November 18, 2024 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provide...

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update – Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 – – 16 patients enrolled with 10 patients dosed as of November 12 across the RESET™ clinical development program; 40 U.S. clinical sites actively recruiting patients – – Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201 – – C...

November 14, 2024 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Inno...

Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Monday, November 11, 2024, at 10:00 a.m. ET in Boston, MA. A live webcast of the presentation will be available ...

November 6, 2024 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in ...

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 PHILADELPHIA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced two presentations at the upcoming American College of Rheumatology (ACR) Convergence 2024, which is being held at the Walter E. Washington Convention Center in Washington, D.C. from November ...

September 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch